Latest market price
20.47
-0.12-0.58%
OverviewShort InterestFilings
ACADQT49Acadia Pharmaceuticals Inc.·NASDAQ
20.47-0.58%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AMLX-2.84%$28.04ABCL-9.37%$11.12TARS-2.04%$73.32IOVA-5.42%$8.02XENE+0.56%$37.62VKTX-1.65%$26.83TNGX-4.23%$21.76RLAY-5.83%$17.28
Snapshot
Index—P/E9.22EPS (ttm)2.22Insider Own46.62%Shs Outstand172.31MPerf Week3.70%
Market Cap3.53BForward P/E21.82EPS next Y0.94Insider Trans-0.07%Shs Float170.04MPerf Month2.61%
Enterprise Value2.63BPEG0.21EPS next Q0.20Short Float5.35%Perf Quarter-24.60%
Income382.00MP/S3.10EPS this Y-22.98%Short Ratio4.88Perf Half Y-7.75%
Sales1.14BP/B2.70EPS next Y50.50%ROA21.83%Short Interest9.09MPerf YTD-23.36%
Book/sh7.59P/C3.69EPS next 5Y43.17%ROE32.39%52W High30.96 -33.88%Perf Year-9.98%
Cash/sh5.55P/FCF20.27EPS past 3/5Y—ROIC6.19%52W Low18.39 11.31%Perf 3Y-9.02%
Dividend Est.—EV/EBITDA22.68Sales past 3/5Y27.52% 19.39%Gross Margin91.13%Volatility2.51% 2.90%Perf 5Y17.91%
Dividend TTM—EV/Sales2.31EPS Y/Y TTM66.92%Oper. Margin7.59%ATR (14)0.66Perf 10Y-19.22%
Dividend Ex-Date—Quick Ratio3.30Sales Y/Y TTM11.78%Profit Margin33.42%RSI (14)44.48Recom2.35
Dividend Gr. 3/5Y—Current Ratio3.39EPS Q/Q12.50%SMA203.02%Beta0.89Target Price29.95
Payout0.00%Debt/Eq0.05Sales Q/Q16.23%SMA50-13.11%Rel Volume0.74Prev Close20.59
Employees797LT Debt/Eq0.05EarningsNov 04SMA200-13.45%Avg Volume1.86MPrice20.47
IPO DateMay 27, 2004Option/ShortYes / YesEPS/Sales Surpr.164.12% 3.85%Net Debt/EBITDA-7.72Volume1,381,718Change-0.58%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-13-26DowngradeUBSBuy → Neutral$49 → $23
Sep-28-26ReiteratedWilliam Blair$29 → $33
Sep-25-26ReiteratedBMO CapitalOutperform$36 → $34
Sep-25-26ReiteratedNeedhamBuy$41 → $35
Sep-25-26ReiteratedDeutsche BankBuy$38 → $31
Sep-25-26ReiteratedHC Wainwright & Co.Buy$37 → $33
Sep-24-26ReiteratedNeedhamBuy$41 → $35
Aug-25-26ReiteratedDeutsche BankBuy$37 → $38
Aug-25-26ReiteratedMorgan StanleyEqual Weight$27 → $28
Aug-17-26ReiteratedUBSBuy$40 → $49
Latest News· Times ET
Oct-28-26
Oct-28-2604:05PM
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026Yahoo
11:06AM
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Declinezacks.com
Oct-27-26
Oct-27-2606:43PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADglobenewswire.com
Oct-21-26
Oct-21-2604:05PM
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026Yahoo
Oct-20-26
Oct-20-2604:14PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADglobenewswire.com
Oct-19-26
Oct-19-2608:07AM
Needham & Company LLC Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)defenseworld.net
02:07AM
Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price TargetBenzinga
Oct-13-26
Oct-13-2605:08PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADglobenewswire.com
02:01PM
Top Midday DeclinersYahoo
11:06AM
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?zacks.com
Oct-12-26
Oct-12-2602:15AM
Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)defenseworld.net
Oct-09-26
Oct-09-2611:31AM
4 CNS Drug Stocks Worth Watching This World Mental Health Dayzacks.com
Oct-06-26
Oct-06-2605:02PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADglobenewswire.com
Oct-05-26
Oct-05-2609:07PM
Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?Yahoo
Sep-29-26
Sep-29-2605:29PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADglobenewswire.com
Company

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,1391,072958726—————
Cost of Goods Sold Incl. D&A101898246—————
Gross Profit1,038983876681—————
Selling, General and Administrative Excl. Other620549488402—————
Research and Development332329303352—————
Other Operating Expense-10-1460—————
Operating Income86105231-73—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)36342722—————
Net Income Before Taxes121139258-51—————
Income Taxes-259-2523210—————
Consolidated Net Income382391226-61—————
Net Income From Continuing Operations382391226-61—————
Net Income382391226-61—————
EPS (Recurring)2.252.321.37-0.37—————
EPS (Basic, Before Extraordinaries)2.252.321.37-0.37—————
EPS (Diluted)2.222.291.36-0.37—————
EBITDA116151100-45—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio9.2211.6613.49——————
Price To Sales Ratio3.094.213.187.07—————
Gross Margin91.1391.7091.4493.80—————
Operating Margin7.559.7924.11-10.06—————
Net Margin33.5436.4723.59-8.40—————
Shares Outstanding172169166164—————
Market Capitalization3,5214,5143,0465,135—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$32.36$28.48$24.59$20.71$16.83● Close Price0.00M0.25M0.51M0.76M1.01MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICEROct 30 '26Sale20.883,32169,34271,322Oct 30
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 06 '26Sale29.2214,292417,60467,828Aug 07
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 06 '26Option Exercise17.8414,292254,96982,120Aug 07
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 05 '26Sale29.005,849169,63867,828Aug 07
Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICERAug 05 '26Option Exercise17.845,849104,34673,677Aug 07
Thompson Elizabeth H.Z.EVP, Head of Research & DevJul 30 '26Sale26.1316,558432,66318,994Jul 31
Thompson Elizabeth H.Z.EVP, Head of Research & DevJul 29 '26Option Exercise0.0032,272035,552Jul 31
Kihara JamesPRINCIPAL ACCOUNTING OFFICERJun 26 '26Sale26.0811,421297,91213,088Jun 29
Daly James MDirectorMay 29 '26Option Exercise0.008,107012,148Jun 01
Brege LauraDirectorMay 29 '26Option Exercise0.008,107023,202Jun 01
HARRIGAN EDMUNDDirectorMay 29 '26Option Exercise0.008,107043,148Jun 01
Ndu AdoraDirectorMay 29 '26Option Exercise0.008,107032,908Jun 01
Poole JonathanDirectorMay 29 '26Option Exercise0.002,01002,010Jun 01
GAROFALO ELIZABETH A.DirectorMay 29 '26Option Exercise0.008,107033,489Jun 01
Kihara JamesPRINCIPAL ACCOUNTING OFFICERMay 26 '26Sale21.185,401114,39324,509May 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.